Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Gains from Sales and Divestitures (2021 - 2025)

iBio (IBIO) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $35369.0 as the latest value for Q2 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 15.9% to $35369.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $35369.0, a 15.9% decrease, with the full-year FY2025 number at $35369.0, down 15.9% from a year prior.
  • Gains from Sales and Divestitures was $35369.0 for Q2 2025 at iBio, up from $11575.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $42054.0 in Q2 2024 to a low of $11.0 in Q3 2024.
  • A 5-year average of $11366.8 and a median of $4709.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 1008.44% in 2022, then plummeted 99.78% in 2024.
  • iBio's Gains from Sales and Divestitures stood at $4120.0 in 2021, then surged by 114.9% to $8854.0 in 2022, then tumbled by 44.08% to $4951.0 in 2023, then tumbled by 99.78% to $11.0 in 2024, then surged by 321436.36% to $35369.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Gains from Sales and Divestitures are $35369.0 (Q2 2025), $11575.0 (Q1 2025), and $11.0 (Q4 2024).